vTv Therapeutics Management
Management criteria checks 3/4
vTv Therapeutics' CEO is Paul Sekhri, appointed in Aug 2022, has a tenure of 2.33 years. total yearly compensation is $650.91K, comprised of 73.7% salary and 26.3% bonuses, including company stock and options. directly owns 0.19% of the company’s shares, worth $91.33K. The average tenure of the management team and the board of directors is 2 years and 0.8 years respectively.
Key information
Paul Sekhri
Chief executive officer
US$650.9k
Total compensation
| CEO salary percentage | 73.7% |
| CEO tenure | 2.3yrs |
| CEO ownership | 0.2% |
| Management average tenure | 2yrs |
| Board average tenure | less than a year |
Recent management updates
Recent updates
Here's Why We're Watching vTv Therapeutics' (NASDAQ:VTVT) Cash Burn Situation
Aug 24
Will vTv Therapeutics (NASDAQ:VTVT) Spend Its Cash Wisely?
May 11vTv Therapeutics GAAP EPS of -$0.04
Aug 16vTv stock soars 18% on $10M equity investment by CinRx Pharma
Jul 25We Think vTv Therapeutics (NASDAQ:VTVT) Needs To Drive Business Growth Carefully
Aug 17The Director of vTv Therapeutics Inc. (NASDAQ:VTVT), Richard Nelson, Just Bought A Few More Shares
Mar 03vTv Therapeutics inks licensing deal for HPP971, shares up 11%
Dec 15CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$18m |
| Jun 30 2024 | n/a | n/a | -US$20m |
| Mar 31 2024 | n/a | n/a | -US$21m |
| Dec 31 2023 | US$651k | US$480k | -US$20m |
| Sep 30 2023 | n/a | n/a | -US$22m |
| Jun 30 2023 | n/a | n/a | -US$19m |
| Mar 31 2023 | n/a | n/a | -US$17m |
| Dec 31 2022 | US$2m | US$200k | -US$19m |
Compensation vs Market: Paul's total compensation ($USD650.91K) is about average for companies of similar size in the US market ($USD653.16K).
Compensation vs Earnings: Paul's compensation has been consistent with company performance over the past year.
CEO
Paul Sekhri (66 yo)
2.3yrs
Tenure
US$650,913
Compensation
Mr. Paul J. Sekhri, M.Sc. is Director of Quercis Pharma AG. Mr. Sekhri is Director at AdhereTech Inc. since February 7, 2024. He serves as Chief Executive Officer, President & Director of vTv Therapeutics...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Chairman of the Board | 2.3yrs | US$650.91k | 0.19% $ 91.3k | |
| Executive VP & CFO | 2yrs | US$465.25k | 0.20% $ 95.1k | |
| Chief Scientific Officer & Executive VP | no data | no data | no data | |
| Executive VP & General Counsel | 1.8yrs | no data | no data | |
| Executive VP of Corporate Development & Director | 2.3yrs | US$547.40k | 0.42% $ 198.7k | |
| Chief Medical Officer | 1.1yrs | no data | no data |
2.0yrs
Average Tenure
56.5yo
Average Age
Experienced Management: VTVT's management team is considered experienced (2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Chairman of the Board | 2.3yrs | US$650.91k | 0.19% $ 91.3k | |
| Executive VP of Corporate Development & Director | 4.1yrs | US$547.40k | 0.42% $ 198.7k | |
| Director | less than a year | no data | no data | |
| Independent Director | less than a year | no data | no data | |
| Independent Director | less than a year | no data | no data | |
| Lead Independent Director | less than a year | no data | no data | |
| Independent Director | 2.4yrs | US$87.63k | 0.024% $ 11.4k |
0.8yrs
Average Tenure
56yo
Average Age
Experienced Board: VTVT's board of directors are not considered experienced ( 0.8 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 04:28 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
vTv Therapeutics Inc. is covered by 10 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Molloy | Alliance Global Partners |
| Corey Davis | Canaccord Genuity |
| Charles Duncan | Cantor Fitzgerald & Co. |